Body recomposition.

The Body Recomposition Stack: Three Tiers Targeting Three Rate-Limiting Steps

True body recomposition — simultaneously reducing fat mass while increasing or preserving lean mass — is physiologically demanding in a way that pure cutting or pure bulking is not. The body's partitioning signals (which macronutrients go to fat vs. muscle) are primarily governed by the GH/IGF-1 axis, insulin sensitivity, and tissue repair capacity. Each tier of this stack addresses one of those levers directly.

Tier 1: GH Axis Activation with Visceral Fat Selectivity — Tesamorelin

Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), the endogenous hypothalamic signal that drives pulsatile GH secretion from the pituitary. By amplifying the physiological GHRH signal, Tesamorelin increases GH release in a pattern that mimics — rather than overrides — the natural pulsatile rhythm. This matters mechanistically: supraphysiological GH (from exogenous GH injection) produces blunted receptor sensitivity over time; Tesamorelin's pulse-amplification approach avoids this adaptation.

The most pharmacologically distinctive property of Tesamorelin is its selective action on visceral adipose tissue (VAT) rather than subcutaneous fat. VAT — the fat surrounding the internal organs in the abdominal cavity — is metabolically active in a way subcutaneous fat is not: it secretes pro-inflammatory cytokines (TNF-alpha, IL-6), drives hepatic insulin resistance via portal circulation exposure, and is the fat depot most strongly associated with cardiovascular risk and metabolic syndrome. The GH-driven lipolytic signal preferentially targets VAT over subcutaneous fat, providing fat loss that tracks directly with metabolic health improvements rather than merely aesthetic ones.

FDA approval of EGRIFTA (tesamorelin injection) for HIV-associated lipodystrophy provides a controlled clinical validation that no comparable research peptide possesses. The pivotal trials demonstrated an 18% reduction in visceral fat as measured by CT imaging over 26 weeks, with simultaneous preservation of lean mass and subcutaneous fat — a uniquely selective lipolytic profile (PMID: 20554713). A comprehensive clinical pharmacology review (PMID: 22298602) summarizes Tesamorelin's mechanism, safety profile, and regulatory pathway, providing the mechanistic context for its application beyond the HIV-associated indication.

Tier 2: Selective GH Secretagogue Without Cortisol or Prolactin Elevation — Ipamorelin

Ipamorelin acts on the ghrelin receptor (growth hormone secretagogue receptor, GHSR), providing a complementary GH-releasing mechanism to Tesamorelin's GHRH-receptor action. The mechanistic synergy is well-established: GHRH (Tesamorelin) stimulates GH release; somatostatin simultaneously inhibits it. Ipamorelin specifically suppresses somatostatin's inhibitory action while simultaneously stimulating GHSR — the result is a significantly larger net GH pulse than either compound achieves alone.

Ipamorelin's defining competitive advantage over other GH secretagogues (GHRP-6, GHRP-2, hexarelin) is its remarkable selectivity. Early characterization studies demonstrated that Ipamorelin produces the same magnitude of GH release as equivalent doses of other GHRPs while uniquely failing to stimulate ACTH, cortisol, or prolactin (PMID: 9849822). This matters for body recomposition: cortisol is catabolic to muscle and lipogenic in the visceral fat depot — it is the hormonal environment that prevents recomposition. Every GHRP-class compound except Ipamorelin produces some cortisol co-stimulation, partially undermining its own anabolic utility. Ipamorelin's clean GH pulse preserves the anabolic environment required for simultaneous fat loss and lean mass maintenance.

Beyond fat mass, Ipamorelin's GH secretagogue effect provides downstream anabolic signaling through IGF-1 production. Animal studies demonstrate that GH secretagogues in the ipamorelin class increase bone mineral content and lean tissue mass — evidence that the GH axis activation has genuine anabolic consequences beyond fat mobilization (PMID: 10828840). For body recomposition, this secondary anabolic signal is the mechanism connecting GH axis optimization to measurable lean mass preservation.

Tier 3: Training Continuity and Connective Tissue Resilience — BPC-157

BPC-157 is the enabling tier in the body recomposition stack — the compound that makes the training volume required for simultaneous lean mass preservation physiologically sustainable. Recomposition requires consistent, high-frequency resistance training to maintain the mechanical stimulus for muscle protein synthesis while Tesamorelin and Ipamorelin drive fat mobilization. Without BPC-157's connective tissue support, the training load required to preserve lean mass during a recomposition protocol often produces cumulative tendon and ligament stress that forces training interruptions.

BPC-157's mechanism for enabling training continuity is multifactorial: it upregulates VEGF at injury sites (restoring capillary supply to the avascular tendon tissue damaged by high-load training), directly stimulates fibroblast proliferation and tendon cell outgrowth (PMID: 21030672), and activates the FAK-paxillin signaling pathway in connective tissue cells. Practically, this translates to faster recovery from the micro-trauma of high-intensity training and lower accumulated structural risk over a 12-16 week recomposition protocol — allowing the training volume that drives lean mass preservation to remain constant rather than tapering due to joint load tolerance.

The gut-brain axis dimension of BPC-157 is also relevant for recomposition: BPC-157 modulates the nitric oxide system to protect gastric mucosa, which is directly relevant for athletes training in a caloric deficit (where gastric stress from NSAID use and reduced gut blood flow during intense exercise is elevated). A functioning gut-immune axis optimizes nutrient partitioning — protein absorption and amino acid bioavailability are prerequisite for the muscle protein synthesis response to training that body recomposition depends on.

Clinical and Preclinical Evidence for the Recomposition Stack

The evidence base for this stack spans FDA-approved Phase 3 clinical trials (Tesamorelin), targeted mechanistic studies (Ipamorelin, BPC-157), and pharmacological characterization reviews. The clinical depth of the Tesamorelin evidence base is exceptional among research peptides and provides the evidentiary anchor for the stack.

Tesamorelin: Phase 3 Clinical Trial Data

The pivotal evidence for Tesamorelin comes from a pooled analysis of two Phase 3 RCTs (PMID: 20554713) involving 412 HIV-infected patients with excess visceral abdominal fat. Tesamorelin produced a statistically significant 18% reduction in VAT as measured by CT imaging over 26 weeks compared to no significant change in placebo. Critically, lean mass and subcutaneous fat were both preserved — confirming the VAT-selective lipolytic profile rather than generalized tissue catabolism. IGF-1 rose into the upper-normal range in the Tesamorelin group, confirming GH axis activation consistent with the mechanism. A 2020 study (PMID: 32701508) demonstrated that Tesamorelin significantly reduced hepatic steatosis in HIV patients with NAFLD — extending the visceral fat evidence to the liver compartment and demonstrating metabolic consequence beyond adipose tissue alone. A comprehensive pharmacology review (PMID: 22298602) documents Tesamorelin's mechanism of action, pharmacokinetic properties, and clinical evidence base, providing the mechanistic bridge between the HIV-associated approval data and broader body composition applications.

Ipamorelin: Selectivity and Anabolic GH Signal

Ipamorelin's Phase 1 characterization study (PMID: 9849822) established the compound's defining property: dose-dependent GH release equivalent in magnitude to GHRP-6 and GHRP-2, but with uniquely absent co-stimulation of ACTH, cortisol, and prolactin. This study, which compared Ipamorelin directly against GHRP-6 and hexarelin in the same subjects, is the evidentiary foundation for Ipamorelin's position as the preferred GH secretagogue for body recomposition — where cortisol co-stimulation would directly counteract the desired anabolic-catabolic partitioning. A bone mineral content study (PMID: 10828840) examined GH secretagogues including ipamorelin class compounds and found significant increases in bone mineral content in the treatment group relative to controls, providing evidence that the GH axis activation produces measurable anabolic downstream consequences in hard tissue — consistent with soft tissue lean mass preservation expected from GH/IGF-1 elevation.

BPC-157: Connective Tissue Protection Under Training Load

The body of preclinical research on BPC-157 for tendon and ligament healing is extensive. The Chang 2011 study (PMID: 21030672) isolated the specific mechanism by which BPC-157 promotes connective tissue repair: direct stimulation of tendon fibroblast outgrowth from tendon explants and activation of the FAK-paxillin pathway in tendon cells, confirming that BPC-157's anabolic effect on connective tissue is direct and receptor-mediated. For recomposition applications specifically, this mechanism is relevant as a training-continuity enabler: athletes who can maintain high-frequency resistance training throughout a 12-16 week protocol preserve lean mass more effectively than those whose training is disrupted by accumulated connective tissue injury.

Evidence Limits for General Population Recomposition

The Tesamorelin clinical data is concentrated in HIV-positive patients with lipodystrophy — a condition characterized by pathologically elevated VAT that is not present in healthy subjects. Extrapolating the 18% VAT reduction to healthy subjects seeking recomposition requires acknowledging that the magnitude of effect in subjects with normal VAT baseline will be smaller. The mechanism (GH-driven VAT lipolysis) is the same; the baseline adiposity is different. Ipamorelin and BPC-157 have no large-scale human RCT data in healthy athletes — extrapolation from mechanism and preclinical studies is the evidentiary basis for their recomposition application.

Tracking Body Recomposition Outcomes

Scale weight is the most commonly used and least informative metric for recomposition. Simultaneous fat loss and lean mass gain can produce zero net weight change while dramatically improving body composition. Objective tracking requires direct measurement of body composition, GH axis activity, and metabolic parameters.

• DEXA Scan (Dual-Energy X-ray Absorptiometry) — primary endpoint: The gold standard for body composition measurement. Provides precise fat mass (FM), lean mass (LM), and bone density with regional breakdown (android/gynoid fat distribution, appendicular lean mass index). Run at baseline, week 6, and week 12-16. A successful Tesamorelin/Ipamorelin protocol shows declining trunk fat mass (especially android/visceral region) with stable or increasing appendicular lean mass. Target: reduce android fat mass while maintaining or increasing ALMI (Appendicular Lean Mass Index — lean mass of arms + legs / height²). Men target ALMI ≥ 7.0 kg/m²; women ≥ 5.5 kg/m².
• Waist Circumference and Waist-to-Hip Ratio (WHR): The most accessible proxy for VAT change. Tesamorelin's VAT-selective lipolysis produces a measurable waist circumference reduction even when total weight is stable. WHR target: men <0.90; women <0.85. Waist circumference alone: men <94 cm (low-risk threshold); women <80 cm. Track monthly. Lack of waist reduction after 6 weeks suggests insufficient dosing or inadequate GH axis response.
• Serum IGF-1 (Insulin-Like Growth Factor 1): The direct biomarker for GH axis activity. A successful Tesamorelin + Ipamorelin protocol should raise IGF-1 into the upper-normal range: 150–400 ng/mL for adults, age-adjusted (younger adults target the higher end; adults over 50 should not exceed 300 ng/mL without specialist guidance). IGF-1 above 400 ng/mL in adults represents pharmacological supraphysiological stimulation. Monitor monthly. If IGF-1 fails to rise after 4 weeks, review injection technique, peptide quality, and pituitary reserve.
• Fasting Glucose, Insulin, and HOMA-IR: GH has insulin-antagonizing effects. In healthy metabolically-flexible subjects, the GH axis activation from Tesamorelin/Ipamorelin is well-tolerated metabolically. In subjects with pre-existing insulin resistance or pre-diabetes, the insulin-antagonizing effect of elevated GH can worsen glycemic control. Track fasting glucose (target <100 mg/dL), fasting insulin (target <10 mIU/L), and HOMA-IR = (fasting glucose × fasting insulin) / 405 (target <2.5). A rising HOMA-IR during protocol indicates metabolic stress requiring dose adjustment or protocol pause.
• HbA1c (every 12 weeks): Provides a 3-month average glycemic picture that catches sustained insulin antagonism not visible in single fasting glucose readings. Target: <5.7% (non-diabetic range). In the Tesamorelin Phase 3 trials, small but significant rises in fasting glucose and HbA1c were observed in the treatment group compared to placebo — this is a known class effect of GHRH analogs. Monitor accordingly.

Alternative Stacks and When to Use Each

The Tesamorelin + Ipamorelin + BPC-157 framework is optimized for subjects with significant visceral adiposity who also want to preserve or gain lean mass. Different body composition profiles require different primary levers.

The Pure Cut Protocol: When to Prioritize Fat Loss Over Recomposition

True simultaneous recomposition is most efficient when body fat is in the moderate range (men 18-25%, women 28-35%). At higher body fat levels (>30% men / >40% women), the priority shifts from recomposition to aggressive fat reduction first — a dedicated cut phase — before adding the lean mass preservation layer. For subjects in this range, a GLP-1 agonist (semaglutide or tirzepatide) as the primary compound, potentially combined with Ipamorelin to preserve GH axis signaling and lean mass during aggressive energy deficit, is more appropriate than the Tesamorelin-led recomposition stack. Tesamorelin's VAT-selectivity is most valuable when visceral fat is the dominant problem, not when total fat mass is very high. Decision rule: If body fat % >30% (men) / >40% (women), prioritize GLP-1-led cut first. Switch to Tesamorelin-led recomposition when body fat enters the moderate range.

The GLP-1 Recomposition Hybrid: Semaglutide + Ipamorelin

For individuals with high baseline body fat and poor insulin sensitivity, a GLP-1 agonist provides aggressive systemic fat reduction via appetite suppression and improved insulin sensitivity, while Ipamorelin maintains the GH pulse to limit lean mass catabolism during the energy deficit. This hybrid addresses a limitation of the Tesamorelin-only approach: Tesamorelin requires adequate endogenous somatotroph capacity, which may be reduced in subjects with obesity-related GH suppression. GLP-1 agonists improve the hormonal environment (reducing GH suppression from obesity) while Ipamorelin drives the GH pulse more directly. Tradeoff: GLP-1's profound appetite suppression makes adequate protein intake (minimum 2.2g/kg/day) difficult — this stack requires rigorous protein tracking to prevent lean mass catabolism. The Tesamorelin + Ipamorelin approach without GLP-1 does not carry this lean mass risk.

Resistance Training + Caloric Cycling: The Non-Peptide Baseline

For lean subjects (men <18%, women <28%) who are already resistance training consistently, body recomposition is achievable with caloric cycling alone (slight deficit on rest days, maintenance or surplus on training days, with protein fixed at 2.2-2.5g/kg/day). Systematic reviews of natural recomposition demonstrate that beginners, detrained individuals, and subjects in slight caloric deficit can achieve meaningful simultaneous fat loss and lean mass gain without any peptide intervention, provided training stimulus is adequate. The research peptide stack accelerates the process and may enable recomposition at higher training intensities and with less nutritional precision — but it is not the prerequisite. The honest framing: Tesamorelin/Ipamorelin produce a measurable GH axis effect that diet and training cannot replicate; BPC-157 addresses connective tissue tolerance that training volume alone cannot overcome. These are real advantages — but the non-peptide baseline is more effective than most subjects realize before escalating to pharmacological support.

Testosterone and SARMs: The Anabolic Alternative with HPG Axis Costs

Testosterone replacement and SARMs (Selective Androgen Receptor Modulators) produce substantially larger lean mass gains than GH axis peptides — primarily through androgen receptor-mediated muscle protein synthesis, a mechanistically distinct and more potent anabolic pathway. However, exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis: LH and FSH fall, endogenous testosterone production is suppressed to clinically negligible levels during administration, and testicular atrophy typically progresses within weeks. SARMs produce similar HPG axis suppression with less androgenic side-effect profile. Both require post-cycle therapy (PCT) to restore endogenous HPG axis function, which is unpredictable in timeline and not always complete. The distinction: Tesamorelin and Ipamorelin stimulate rather than suppress endogenous hormone production — they amplify the physiological GH axis without replacing it. This is the fundamental HPG-axis-sparing property that positions GH axis peptides as appropriate for long-duration protocols where maintaining endogenous hormone function is a priority.